Sepsis‐induced acute kidney injury: A disease of the microcirculation
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
AKI is a common complication of sepsis and is significantly associated with mortality. Sepsis accounts for more than 50% of the cases of AKI, with a mortality rate of up to 40%. The pathogenesis of septic AKI is complex, but there is emerging evidence that, at least in the first 48 hours, the defects may be functional rather than structural in nature. For example, septic AKI is associated with an absence of histopathological changes, but with microvascular abnormalities and tubular stress. In this context, renal medullary hypoxia due to redistribution of intra‐renal perfusion is emerging as a critical mediator of septic AKI. Clinically, vasopressor drugs remain the cornerstone of therapy for maintenance of blood pressure and organ perfusion. However, in septic AKI, there is insensitivity to vasopressors such as norepinephrine, leading to persistent hypotension and organ failure. Vasopressin, angiotensin II, and, paradoxically, α 2‐adrenergic receptor agonists (clonidine and dexmedetomidine) may be feasible adjunct therapies for catecholamine‐resistant vasodilatory shock. In this review, we outline the recent progress made in understanding how these drugs may influence the renal microcirculation, which represents a crucial step toward developing better approaches for the circulatory management of patients with septic AKI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621 · cited 9×
“Volume resuscitation, vasopressor therapy, antimicrobial therapy and renal replacement therapy remain the mainstays of the management for sepsis-induced AKI in the ICU [96].”
BackgroundInfluentialFleischmann, C., Scherag, A., Adhikari, N. K. J., Hartog, C. S., Tsaganos, T., Schlattmann, P., Angus, D. C., & Reinhart, K. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0781oc · Cited by 3,548
A randomized trial of protocol-based care for early septic shock.
The ProCESS Investigators (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401602 · Cited by 2,414
Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock
Russell, J. A., Walley, K. R., Singer, J., Gordon, A. C., Hébert, P. C., Cooper, D. J., Holmes, C. L., Mehta, S., Granton, J. T., Storms, M. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa067373 · Cited by 1,924
Trial of early, goal-directed resuscitation for septic shock.
Mouncey, P. R., Osborn, T. M., Power, G. S., Harrison, D. A., Sadique, M. Z., Grieve, R. D., Jahan, R., Harvey, S. E., Bell, D., Bion, J. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500896 · Cited by 1,604
High versus low blood-pressure target in patients with septic shock.
Asfar, P., Meziani, F., Hamel, J.-F., Grelon, F., Megarbane, B., Anguel, N., Mira, J.-P., Dequin, P.-F., Gergaud, S., Weiss, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312173 · Cited by 1,239 · cited 1×
“Vasopressor Therapy Norepinephrine: In septic shock, norepinephrine is the first-choice vasopressor recommended to restore mean arterial blood pressure to ≥65 mmHg [96], and potentially even to levels above 80 mmHg in patients with pre-existing hypertension [5].”
BackgroundAngiotensin II for the Treatment of Vasodilatory Shock
Khanna, A., English, S. W., Wang, X. S., Ham, K., Tumlin, J., Szerlip, H., Busse, L. W., Altaweel, L., Albertson, T. E., Mackey, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704154 · Cited by 916 · cited 1×
“After these initial safety and feasibility studies, a randomized, double-blinded, multicenter clinical trial in more than 300 patients with catecholamine-refractory vasodilatory shock validated angiotensin II as an effective rescue vasopressor to restore blood pressure (Angiotensin II for Treatment of High Output Shoc…”
BackgroundSelf-citationA comparison of epinephrine and norepinephrine in critically ill patients
Myburgh, J. A., Higgins, A., Jovanovska, A., Lipman, J., Ramakrishnan, N., Santamaria, J., & the CAT Study investigators (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1219-0 · Cited by 368 · cited 1×
“However, norepinephrine therapy has been shown to consistently reverse hypotension and transiently improve renal function in septic shock, as evaluated by estimated glomerular filtration rate, with fewer adverse effects than dopamine, vasopressin, epinephrine, or phenylephrine [29,81,85,98].”
BackgroundIntrarenal oxygenation: unique challenges and the biophysical basis of homeostasis
Evans, R. G., Gardiner, B. S., Smith, D. W., & O'Connor, P. M. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90230.2008 · Cited by 274 · cited 2×
“Consequently, renal oxygen consumption is directly linked to the filtered load of sodium, and thus glomerular filtration rate [40].”
BackgroundSelf-citationIntravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study
Chawla, L. S., Busse, L., Brasha-Mitchell, E., Davison, D., Honiq, J., Alotaibi, Z., & Seneff, M. G. (2014) · Critical Care · doi:10.1186/s13054-014-0534-9 · Cited by 197 · cited 1×
“In a pilot study in patients with catecholamine-resistant septic shock, angiotensin II effectively restored blood pressure and doubled renal function [22].”
Background
Cited by
Ronco, C., Bellomo, R., & Kellum, J. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32563-2 · Cited by 1,910
Self-citation
Metadata
- Authors
- Ma, S., Evans, R. G., Iguchi, N., Tare, M., Parkington, H. C., Bellomo, R., May, C. N., & Lankadeva, Y. R.
- Venue
- Microcirculation
- Publisher
- Wiley
- Published
- 2018-07-18
- Volume
- 26
- Issue
- 2
- Pages
- e12483-e12483
- ISSN
- 1073-9688 (ISSN-L)
- 1549-8719
- OpenAlex
- W2808694326
- Cited by
- 181
- References
- 11
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.